Health Care's Winning Quarter: Turning Industry Momentum into Market Advantage

IMC Board
Dec 3, 2025
7 min read

What if the sector facing the most regulatory scrutiny and policy uncertainty just delivered the strongest quarterly performance in over four years?

That's exactly what happened in Q3 2025 when health care companies topped all other S&P 500 industries in earnings beats. For insurance carriers, agents, and marketers operating in this space, understanding the forces behind this outperformance is essential for strategic planning, client conversations, and market positioning.

Key Takeaways

Health care companies achieved the highest earnings beat rate across all S&P 500 sectors in Q3 2025, marking their strongest quarterly performance in over four years.
Specialty drug demand exceeded historical levels, with cancer treatments, autoimmune therapies, and weight-loss medications driving pharmaceutical distributor and manufacturer success.
Commercial and Medicare Advantage utilization remained stable and lower than expected—good news for carriers in these segments—while Medicaid and Affordable Care Act (ACA) exchange plans faced continued pressure from elevated medical costs.
Hospital systems benefited from increased complex service utilization, potentially reflecting patients accelerating benefit usage amid ACA subsidy uncertainty, which could create timing implications for 2026 utilization patterns.
Medical device manufacturers successfully navigated tariff concerns in Q3 though the full-year 2026 impact remains unclear as tariffs only took effect in August.
Drug pricing policy clarity is creating more predictable pharmacy benefit management environments, potentially benefiting insurers with improved actuarial forecasting.
Three forward-looking trends demand attention: pharmaceutical research and development (R&D) acceleration, evolving tariff impacts on device pricing, and sustained procedural volume growth driven by an aging, active population.

Numbers Tell a Compelling Story

Health care companies achieved the highest rate of earnings beats among the eleven S&P 500 industry categories during the third quarter, marking their strongest quarterly showing since 2021. This wasn't a fluke or the result of a single blockbuster drug. Instead, multiple tailwinds converged across pharmaceuticals, hospitals, medical devices, and even parts of the insurance sector.

The performance is noteworthy given the issues that the industry faces. Political debates around drug pricing, ongoing questions about ACA subsidies, and Medicaid policy uncertainties haven't disappeared. And yet health care companies found ways to deliver.

Key Drivers Behind the Health Care Surge

Understanding what propelled health care to the top of the earnings leaderboard requires looking beyond headline numbers. Five distinct forces combined to create this performance, each with specific implications for how insurers manage risk, how agents advise clients, and how the health care economy will likely evolve through 2026. These trends are concrete shifts in utilization, pricing power, and patient behavior that directly impact your business model.

1. Specialty Drug Demand Reaches New Heights

The pharmaceutical distribution giants—McKesson, Cencora, and Cardinal Health—rode a wave of specialty medication demand that exceeded historical patterns. Cancer treatments, autoimmune therapies, and urology medications drove especially strong results, with these high-margin specialty drugs offsetting pricing pressures in traditional generics.

For insurance carriers, this trend has dual implications. On one hand, specialty drug spending continues to be a significant cost driver requiring sophisticated utilization management. On the other, the shift toward specialty medications often means better patient outcomes in complex conditions, potentially reducing downstream medical costs.

2. Weight-Loss Drugs Continue Market Transformation

Eli Lilly's earnings beat was substantially driven by demand for its weight loss and diabetes medications, reflecting the ongoing glucagon-like peptide-1 (GLP-1) revolution that's reshaping both pharmaceutical earnings and health care utilization patterns. These drugs, which include Mounjaro and Zepbound, are creating entirely new treatment paradigms for obesity and diabetes management.

Insurance agents should be prepared for increasingly sophisticated client questions about GLP-1 coverage. Employers are weighing the upfront costs against potential long-term savings from reduced complications. According to research from the Yale School of Public Health, Medicare could save up to $60 billion over a decade if GLP-1 drugs were fully covered for obesity treatment.

3. Hospital Utilization Patterns Shifted

HCA Healthcare and Tenet Healthcare saw improved profits partly due to higher Medicaid supplemental payments and increased use of complex services. Weather also played a supporting role, with normal conditions allowing consistent operations compared to the prior year's hurricane disruptions.

There's an intriguing subplot here: some of the hospital strength may reflect patients accelerating their use of benefits amid uncertainty about future ACA subsidies and premiums. This creates a potential timing issue for insurers as higher utilization in late 2025 could mean pulled-forward demand that moderates in 2026.

4. Medical Device Makers Navigated Tariff Concerns

Device manufacturers defied expectations by managing tariff impacts better than analysts predicted. Steady procedural volumes, cost management, and an aging population seeking elective procedures all contributed to earnings beats across the sector.

The U.S. medical device market is projected to grow from $199.06 billion in 2025 to $314.96 billion by 2032, at a compound annual growth rate (CAGR) of 6.8%, driven by technological advances and demographic trends. For insurers, this means continued innovation in treatment options and continued negotiations over coverage and reimbursement for new technologies.

5. Commercial and Medicare Advantage Utilization Stayed Rational

Here's potentially the best news for insurance carriers: commercial and Medicare Advantage utilization remained stable and lower than analysts had expected. While Medicaid and ACA exchange plans faced pressure from high medical costs, the core commercial and Medicare Advantage markets showed disciplined utilization patterns.

This divergence is critical for insurance agents to understand when advising clients on plan selection and for carriers when projecting reserves.

Where Strain Points Emerged

Not every health care subsector thrived. Insurers with significant ACA exchange business such as Molina Healthcare and Oscar Health reported earnings misses due to elevated medical costs. This reflects ongoing challenges in the individual market, where risk adjustment and subsidy structures continue to evolve.

The medical device sector also showed that high valuations can be unforgiving. Stryker faced questions about its Medical Surgical division while Dexcom struggled with manufacturing issues affecting its continuous glucose monitors. These stumbles remind us that execution matters; strong industry trends don't guarantee success for every company.

According to U.S. Food and Drug Administration (FDA) data, medical device recalls increased almost 25% in 2024 compared to 2023, highlighting quality control as an ongoing industry challenge. Medical device recall events in 2024 reached their highest level since 2020 and more than 10% of them involved The most serious type of recall, Class I recalls, accounted for 10.9% of recalls.

What This Means for Insurance Professionals

The earnings story is compelling, but insights without application have limited value. The real question is how carriers, agents, and marketers can translate these industry dynamics into competitive advantages, better client outcomes, and more effective positioning. The following strategic frameworks aren't theoretical—they're practical responses to the specific trends driving health care's Q3 performance.

For Insurance Carriers: Strategic Implications

The divergence between employer-sponsored and Medicare Advantage performance versus Medicaid and ACA marketplace results suggests that underwriting discipline and market selection matter more than ever. Carriers with balanced books of business can leverage strength in employer-sponsored and Medicare Advantage markets to weather continued turbulence in government-subsidized segments.

Drug pricing clarity, with recent policy frameworks becoming more established, may actually benefit insurers by making pharmacy benefit management more predictable. While the Inflation Reduction Act (IRA)'s Medicare drug price negotiation provisions initially created uncertainty, the framework is now enabling more accurate actuarial projections.

For Agents: Client Conversation Starters

The health care earnings story provides multiple angles for meaningful client discussions:

GLP-1 coverage strategy—How are employers thinking about weight-loss drug coverage in light of the category's proven demand and potential long-term savings?
Specialty drug management—What utilization management tools are carriers deploying to manage the specialty drug trend without compromising care quality?
Medicare Advantage positioning—With Medicare Advantage utilization staying rational, how can agents position these plans to employers considering retiree coverage strategies?
ACA plan considerations—For individual market clients, the earnings results highlight the importance of carrier financial stability when selecting exchange plans.

For Digital Marketers: Content and Positioning Opportunities

This earnings cycle creates natural content hooks:

Educational content explaining specialty drug trends and coverage implications
Comparison tools highlighting carrier financial strength metrics
Thought leadership on managing pharmaceutical innovation costs
Case studies on employers successfully implementing GLP-1 coverage strategies

Looking Ahead: Trends to Watch

Q3's results tell us where health care has been, but forward-looking indicators matter more for strategic planning. Three emerging trends have the potential to reshape the competitive landscape over the next 12-18 months. Each carries specific risks and opportunities that insurance professionals should be monitoring closely, with implications that extend well beyond the next earnings cycle.

1. Pharmaceutical Investment Acceleration

With drug pricing uncertainty easing, pharmaceutical companies may increase R&D investments, potentially leading to more innovative therapies entering the pipeline. This could benefit diagnostics firms, device makers, and clinical research organizations, but it will also create new coverage questions for insurers.

2. Tariff Impact Timeline

Medical device tariffs only took effect in August, and questions remain about their full-year 2026 impact. If device makers face margin pressure, they may push harder on pricing negotiations with insurers and health care systems. Monitoring manufacturer earnings calls in Q4 and Q1 will be essential for forecasting cost trends.

3. Procedure Growth Sustainability

Device makers are counting on continued procedural volume growth, new product launches, and expanded treatment indications to maintain momentum. The aging U.S. population supports this; the Census Bureau projects that adults 65 and older will comprise about 21% to 23% of the population by 2030, up from 17% in 2020.

For insurers, this demographic shift means sustained demand for joint replacements, cardiovascular procedures, and other age-related interventions. Actuarial models should account for not just aging, but an increasingly active senior population seeking quality-of-life procedures.

Sources:

American Academy of Actuaries: Health Insurance Market Dynamics
American Academy of Actuaries: Medicare Advantage Plan Cost Projections for Retiree Group Health Benefit Valuations [DRAFT]
Fortune Business Insights: Medical Device: U.S. Medical Devices Market
KFF: Explaining the Prescription Drug Provisions in the Inflation Reduction Act
Modern Healthcare: Healthcare earnings top S&P 500 behind drug, hospital demand
Modern Healthcare: Medical device recalls hit a four-year high in 2024. Here's why
U.S. Census Bureau: Demographic Turning Points for the United States: Population Projections for 2020 to 2060
U.S. Census Bureau: U.S. Older Population Grew From 2010 to 2020 at Fastest Rate Since 1880 to 1890
U.S. Centers for Medicare & Medicaid Services (CMS): National Health Expenditure Data
U.S. Food & Drug Administration: Medical Device Recalls and Early Alerts

Further Thoughts

Health care's dominance in Q3 earnings reflects fundamental demand drivers that aren't going away: an aging population, pharmaceutical innovation, specialty drug adoption, and improving care delivery models. Yes, policy uncertainty remains around ACA subsidies and Medicaid, and yes, some market segments face pressure. But the overall earnings picture suggests a sector adapting successfully to its challenges.

For insurance carriers, the key is maintaining underwriting discipline while positioning to benefit from innovation. For agents, it's about translating these macro trends into relevant client conversations and informed plan recommendations. For marketers, it's finding ways to make these complex dynamics accessible and actionable for diverse audiences.

The health care sector just proved that it can deliver strong results even in a complicated environment. The question for insurance professionals is: how will you leverage these insights to deliver value to your clients and stakeholders?